Treatment After Palbociclib-containing Regimens

A Multi-center Study of the Treatment Patterns and Clinical Outcomes of Subsequent Therapies After Progression on Palbociclib in HR+/HER2- Metastatic Breast Cancer

To evaluate the prescription patterns and treatment outcomes of subsequent therapies after progression on palbociclib in the real world.

Inclusion Criteria:

1. woman, age > 18 years old
2. Diagnosed with HR+/HER2- Metastatic Breast Cancer
3. Patients received at least one-cycle next-line treatment after progression on combined palbociclib and endocrine therapy
4. Complete medical history was available

Exclusion Criteria:

1. Medical history was incomplete